- Home
- CBAN vs LUNG Comparison
CBAN vs LUNG Comparison
Compare CBAN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- LUNG
- Stock Information
- Founded
- CBAN 1975
- LUNG 1995
- Country
- CBAN United States
- LUNG United States
- Employees
- CBAN N/A
- LUNG N/A
- Industry
- CBAN Major Banks
- LUNG Industrial Specialties
- Sector
- CBAN Finance
- LUNG Health Care
- Exchange
- CBAN Nasdaq
- LUNG Nasdaq
- Market Cap
- CBAN 287.3M
- LUNG 124.0M
- IPO Year
- CBAN 1998
- LUNG 2020
- Fundamental
- Price
- CBAN $17.44
- LUNG $2.78
- Analyst Decision
- CBAN
- LUNG Buy
- Analyst Count
- CBAN 0
- LUNG 6
- Target Price
- CBAN N/A
- LUNG $11.53
- AVG Volume (30 Days)
- CBAN 50.8K
- LUNG 311.3K
- Earning Date
- CBAN 07-23-2025
- LUNG 07-30-2025
- Dividend Yield
- CBAN 2.64%
- LUNG N/A
- EPS Growth
- CBAN 14.66
- LUNG N/A
- EPS
- CBAN 1.43
- LUNG N/A
- Revenue
- CBAN $113,756,000.00
- LUNG $87,473,000.00
- Revenue This Year
- CBAN $18.25
- LUNG $18.02
- Revenue Next Year
- CBAN $7.59
- LUNG $18.17
- P/E Ratio
- CBAN $12.17
- LUNG N/A
- Revenue Growth
- CBAN 3.33
- LUNG 19.84
- 52 Week Low
- CBAN $11.93
- LUNG $2.50
- 52 Week High
- CBAN $18.49
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CBAN 68.69
- LUNG 41.83
- Support Level
- CBAN $16.45
- LUNG $2.52
- Resistance Level
- CBAN $17.38
- LUNG $2.84
- Average True Range (ATR)
- CBAN 0.40
- LUNG 0.16
- MACD
- CBAN 0.18
- LUNG 0.04
- Stochastic Oscillator
- CBAN 89.92
- LUNG 46.36
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.